|
1
|
Moreau P, San Miguel J, Sonneveld P,
Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA,
Ludwig H, Einsele H, et al: Multiple myeloma: ESMO Clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 28 (Suppl 4):iv52–iv61. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Munshi NC, Anderson KC, Bergsagel PL,
Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK,
Harousseau JL, Dimopoulos M, et al: Consensus recommendations for
risk stratification in multiple myeloma: Report of the
International Myeloma workshop consensus panel 2. Blood.
117:4696–4700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anderson KC: The 39th David A. Karnofsky
Lecture: Bench-to-bedside translation of targeted therapies in
multiple myeloma. J Clin Oncol. 30:445–452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar SK, Callander NS, Alsina M,
Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung
HC, Gasparetto C, et al: Multiple myeloma, version 3.2017, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
15:230–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mateos MV, Ocio EM, Paiva B, Rosiñol L,
Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R and San
Miguel JF: Treatment for patients with newly diagnosed multiple
myeloma in 2015. Blood Rev. 29:387–403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rajkumar SV: Multiple myeloma: 2016 update
on diagnosis, risk-stratification, and management. Am J Hematol.
91:719–734. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dmoszynska A, Walter-Croneck A,
Usnarska-Zubkiewicz L, Stella-Holowiecka B, Walewski J, Charliński
G, Jedrzejczak W, Wiater E, Lech-Maranda E, Dytfeld D, et al:
Recommendations of polish myeloma group concerning diagnosis and
therapy of multiple myeloma and other plasmacytic dyscrasias for
2015. Acta Hematol Pol. 46:159–211. 2015.
|
|
9
|
Kyle RA and Rajkumar SV: Criteria for
diagnosis, staging, risk stratification and response assessment of
multiple myeloma. Leukemia. 23:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Voorhees PM and Usmani SZ: The role of
high-dose melphalan and autologous stem cell transplant in the
rapidly evolving era of modern multiple myeloma therapy. Clin Adv
Hematol Oncol. 14:719–728. 2016.PubMed/NCBI
|
|
13
|
Hari P: Recent advances in understanding
multiple myeloma. Hematol Oncol Stem Cell Ther. 10:267–271. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cavo M, Tacchetti P, Patriarca F, Petrucci
MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo
A, et al: Bortezomib with thalidomide plus dexamethasone compared
with thalidomide plus dexamethasone as induction therapy before,
and consolidation therapy after, double autologous stem-cell
transplantation in newly diagnosed multiple myeloma: A randomised
phase 3 study. Lancet. 376:2075–2085. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moreau P, Avet-Loiseau H, Facon T, Attal
M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C,
et al: Bortezomib plus dexamethasone versus reduced-dose
bortezomib, thalidomide plus dexamethasone as induction treatment
before autologous stem cell transplantation in newly diagnosed
multiple myeloma. Blood. 118:5752–5758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moreau P, Hulin C, Macro M, Caillot D,
Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M,
et al: VTD is superior to VCD prior to intensive therapy in
multiple myeloma: Results of the prospective IFM2013-04 trial.
Blood. 127:2569–2574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Durie BG, Hoering A, Abidi MH, Rajkumar
SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R,
et al: Bortezomib with lenalidomide and dexamethasone versus
lenalidomide and dexamethasone alone in patients with newly
diagnosed myeloma without intent for immediate autologous stem-cell
transplant (SWOG S0777): A randomised, open-label, phase 3 trial.
Lancet. 389:519–527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu
W, Cai X, Wu J and Sun Z: (Bortezomib plus
lenalidomide/thalidomide)-vs. (bortezomib or
lenalidomide/thalidomide)-containing regimens as induction therapy
in newly diagnosed multiple myeloma: A meta-analysis of randomized
controlled trials. Ann Hematol. 91:1779–1784. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Landgren O and Iskander K: Modern multiple
myeloma therapy: Deep, sustained treatment response and good
clinical outcomes. J Intern Med. 281:365–382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang H, Zhou L, Peng L, Fu W, Zhang C and
Hou J: Bortezomib-thalidomide-based regimens improved clinical
outcomes without increasing toxicity as induction treatment for
untreated multiple myeloma: A meta-analysis of phase III randomized
controlled trials. Leuk Res. 38:1048–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ludwig H, Viterbo L, Greil R, Masszi T,
Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales
MB, et al: Randomized phase II study of bortezomib, thalidomide,
and dexamethasone with or without cyclophosphamide as induction
therapy in previously untreated multiple myeloma. J Clin Oncol.
31:247–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosinol L, Oriol A, Teruel AI, Hernández
D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera
L, González Y, et al: Superiority of bortezomib, thalidomide, and
dexamethasone (VTD) as induction pretransplantation therapy in
multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood.
120:1589–1596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cavo M, Pantani L, Pezzi A, Petrucci MT,
Patriarca F, Di Raimondo F, Marzocchi G, Galli M, Montefusco V,
Zamagni E, et al: Bortezomib-thalidomide-dexamethasone (VTD) is
superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as
induction therapy prior to autologous stem cell transplantation in
multiple myeloma. Leukemia. 29:2429–2431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Avet-Loisseau H, Leleu X, Roussel M,
Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L,
Voillat L, Mathiot C, et al: Bortezomib plus dexamethasone
induction improves outcome of patients with t(4;14) myeloma but not
outcome of patients with del(17p). J Clin Oncol. 28:4630–4634.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mateos MV, Gutierrez NC, Martín-Ramos ML,
Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI,
Bengoechea E, Martín A, et al: Outcome according to cytogenetic
abnormalities and DNA ploidy in myeloma patients receiving short
induction with weekly bortezomib followed by maintenance. Blood.
118:4547–4553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shaughnessy JD, Zhou Y, Haessler J, van
Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley
J and Barlogie B: TP53 deletion is not an adverse feature in
multiple myeloma treated with total therapy 3. Br J Haematol.
147:347–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
An G, Acharya C, Deng S, Yi S, Xu Y, Qin
X, Sui W, Li Z, Shi L, Zang M, et al: Cytogenetic and clinical
marks for defining high-risk myeloma in the context of bortezomib
treatment. Exp Hematol. 43:168–176.e2. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Neben K, Lokhorst HM, Jauch A, Bertsch U,
Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K,
Pfreundschuh M, et al: Administration of bortezomib before and
after autologous stem cell transplantation improves outcome in
multiple myeloma patients with deletion 17p. Blood. 119:940–948.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sonneveld P, Salwender H, Van Der Holt B,
El Jarari L, Bertsch U, Blau LW, Zweegman S, Weisel KC, Vellenga E,
Pfreundschuh M, et al: Bortezomib induction and maintenance in
patients with newly diagnosed multiple myeloma: Long-term follow-up
of the HOVON-65/GMMG-HD4 trial. Blood. 126:272015.
|
|
30
|
Moreau P, Attal M, Pégourié B, Planche L,
Hulin C, Facon T, Stoppa AM, Fuzibet JG, Grosbois B, Doyen C, et
al: Achievement of VGPR to induction therapy is an important
prognostic factor for longer PFS in the IFM2005-01 trial. Blood.
117:3041–3044. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rajkumar SV, Jacobus S, Callander NS,
Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M and
Greipp PR; Eastern Cooperative Oncology Group, : Lenalidomide plus
high-dose dexamethasone versus lenalidomide plus low-dose
dexamethasone as initial therapy for newly diagnosed multiple
myeloma: An open-label randomised controlled trial. Lancet Oncol.
11:29–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Richardson PG, Weller E, Lonial E,
Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM,
Schlossman RL, et al: Lenalidomide, bortezomib, and dexamethasone
combination therapy in patients with newly diagnosed multiple
myeloma. Blood. 116:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tacchetti P, Terragna C, Galli M, Zamagni
E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini
L, et al: Bortezomib- and thalidomide-induced peripheral neuropathy
in multiple myeloma: Clinical and molecular analyses of a phase 3
study. Am J Hematol. 89:1085–1091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leiba M, Kedmi M, Duek A, Freidman T,
Weiss M, Leiba R, Nagler A and Avigdor A:
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus
bortezomib-thalidomide-dexamethasone (VTD)-based regimens as
induction therapies in newly diagnosed transplant eligible patients
with multiple myeloma: A meta-analysis. Br J Haematol. 166:702–710.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moreau P, Pylypenko H, Grosicki S,
Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak
T, Shubina A, et al: Subcutaneous versus intravenous administration
of bortezomib in patients with relapsed multiple myeloma: A
randomised, phase 3, non-inferiority study. Lancet Oncol.
12:431–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hus I, Walter-Croneck A, Masternak A,
Jurczyszyn A, Usnarska-Zubkiewicz L, Bołkun Ł, Druzd-Sitek A, Rymko
M, Łętowska J, Lech-Marańda E, et al: Real-life experience with
bortezomib-based regimens in elderly patients with newly diagnosed
multiple myeloma and comorbidities: A Polish retrospective
multicenter study. Pol Arch Intern Med. 127:765–774.
2017.PubMed/NCBI
|
|
37
|
Goldschmidt H, Moreau P, Ludwig H,
Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ,
Feng S, et al: Carfilzomib-dexamethasone versus subcutaneous or
intravenous bortezomib in relapsed or refractory multiple myeloma:
Secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma.
59:1364–1374. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Merz M, Salwender H, Haenel M, Mai EK,
Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, et al:
Peripheral neuropathy associated with subcutaneous or intravenous
bortezomib in patients with newly diagnosed myeloma treated within
the GMMG MM5 phase III trial. Haematologica. 101:e485–e487. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Minarik J, Pavlicek P, Pour L, Pika T,
Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J,
et al: Subcutaneous bortezomib in multiple myeloma patients induces
similar therapeutic response rates as intravenous application but
it does not reduce the incidence of peripheral neuropathy. PLoS
One. 10:e01238662015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brioli A, Perrone G, Patriarca F, Pezzi A,
Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano
L, et al: Successful mobilization of PBSCs predicts favorable
outcomes in multiple myeloma patients treated with novel agents and
autologous transplantation. Bone Marrow Transplant. 50:673–678.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kumar S, Dispenzieri A, Lacy MQ, Hayman
SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar
SV and Gertz MA: Impact of lenalidomide therapy on stem cell
mobilization and engraftment post-peripheral blood stem cell
transplantation in patients with newly diagnosed myeloma. Leukemia.
21:2035–2042. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Paripati H, Stewart AK, Cabou S, Dueck A,
Zepeda VJ, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis JF, et
al: Compromised stem cell mobilization following induction therapy
with lenalidomide in myeloma. Leukemia. 22:1282–1284. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumar S, Giralt S, Stadtmauer EA,
Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S,
Munshi N, Niesvizky R, et al: Mobilization in myeloma revisited:
IMWG consensus perspectives on stem cell collection following
initial therapy with thalidomide-, lenalidomide-, or
bortezomib-containing regimens. Blood. 114:1729–1735. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sinha S, Gertz MA, Lacy MQ, Dispenzieri A,
Hayman SR, Buadi FK, Dingli D, Micallef IN, Hogan WJ, Gastineau DA,
et al: Majority of patients receiving initial therapy with
lenalidomide-based regimens can be successfully mobilized with
appropriate mobilization strategies. Leukemia. 26:1119–1122. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Giebel S, Sadus-Wojciechowska M, Halaburda
K, Drozd-Sokolowska J, Wierzbowska A, Najda J, Mendrek W,
Sobczyk-Kruszelnicka M, Nowicki M, Holowiecki J and Czerw T:
Increased efficacy of intermediate-dose cytarabine + G-CSF compared
to DHAP + G-CSF for stem cell mobilization in patients with
lymphoma: An analysis by the polish lymphoma research group. Ann
Hematol. 95:263–269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Harousseau JL, Attal M and Avet-Loiseau H:
The role of complete response in multiple myeloma. Blood.
114:3139–3146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Child JA, Morgan GJ, Davies FE, Owen RG,
Bell SE, Hawkins K, Brown J, Drayson MT and Selby PJ; Medical
Research Council Adult Leukaemia Working Party, : High-dose
chemotherapy with hematopoietic stem cell rescue for multiple
myeloma. N Engl J Med. 348:1875–1883. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang M, Delasalle K, Feng L, Thomas S,
Giralt S, Qazilbash M, Handy B, Lee JJ and Alexanian R: CR
represents an early index of potential long survival in multiple
myeloma. Bone Marrow Transplant. 45:498–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chanan-Kahn A and Giralt S: Importance of
achieving a complete response in multiple myeloma, and the impact
of novel agents. J Clin Oncol. 28:2612–2624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Attal M, Harousseau JL, Facon T, Guilhot
F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D,
Bouabdallah R, et al: Single versus double autologous stem-cell
transplantation for multiple myeloma. N Engl J Med. 349:2495–2502.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cavo M, Tosi P, Zamagni E, Cellini C,
Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S,
Cangini D, et al: Prospective, randomized study of single compared
with double autologous stem-cell transplantation for multiple
myeloma: Bologna 96 clinical study. J Clin Oncol. 25:2434–2441.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Benyamini N, Avivi I, Dann EJ, Zuckerman
T, Lavi N and Katz T: Comparison of engraftment following different
stem cell mobilization modalities in patients with multiple myeloma
treated with a uniform induction regimen containing bortezomib,
cyclophosphamide and dexamethasone. Ann Hematol. 96:461–467. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Blimark CH, Turesson I, Genall A, Ahlberg
L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O,
Mellqvist UH, et al: Outcome and survival of myeloma patients
diagnosed 2008–2015. Real-world data on 4904 patients from the
Swedish Myeloma Registry. Haematologica. 103:506–513. 2018.
View Article : Google Scholar : PubMed/NCBI
|
